Cargando…
Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review)
Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521627/ https://www.ncbi.nlm.nih.gov/pubmed/36129152 http://dx.doi.org/10.3892/ijo.2022.5424 |
_version_ | 1784799882972758016 |
---|---|
author | Ma, Xiaoran Wu, Jibiao Wang, Bin Liu, Cun Liu, Lijuan Sun, Changgang |
author_facet | Ma, Xiaoran Wu, Jibiao Wang, Bin Liu, Cun Liu, Lijuan Sun, Changgang |
author_sort | Ma, Xiaoran |
collection | PubMed |
description | Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immune checkpoint blockades results in only a small fraction of patients benefiting from the treatment. An increasing number of preclinical studies have reported that PD-L1 expression in tumor cells is involved in a number of epigenetic changes, including histone modifications, non-coding RNA regulation and DNA methylation. In addition, multiple epigenetic targeting drugs have been demonstrated to directly or indirectly interfere with PD-L1 expression in various cancer models. This provides opportunities to better characterize the regulatory mechanisms of PD-L1 expression and explore novel therapeutic strategies to improve immunosuppressant response rates and overcome drug resistance. The present review focuses on the latest findings and evidence on the epigenetic mechanism regulating PD-L1 expression and discusses the biological and clinical implications of this regulatory mechanism in solid tumors. A rational combination of epigenetic regulation and PD-1/PD-L1 axis blockade may improve the prognosis of patients with solid tumors. |
format | Online Article Text |
id | pubmed-9521627 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-95216272022-09-30 Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) Ma, Xiaoran Wu, Jibiao Wang, Bin Liu, Cun Liu, Lijuan Sun, Changgang Int J Oncol Articles Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis have achieved marked and durable efficacy in patients with different solid tumors and have improved their survival. However, the presence of primary or acquired resistance to immune checkpoint blockades results in only a small fraction of patients benefiting from the treatment. An increasing number of preclinical studies have reported that PD-L1 expression in tumor cells is involved in a number of epigenetic changes, including histone modifications, non-coding RNA regulation and DNA methylation. In addition, multiple epigenetic targeting drugs have been demonstrated to directly or indirectly interfere with PD-L1 expression in various cancer models. This provides opportunities to better characterize the regulatory mechanisms of PD-L1 expression and explore novel therapeutic strategies to improve immunosuppressant response rates and overcome drug resistance. The present review focuses on the latest findings and evidence on the epigenetic mechanism regulating PD-L1 expression and discusses the biological and clinical implications of this regulatory mechanism in solid tumors. A rational combination of epigenetic regulation and PD-1/PD-L1 axis blockade may improve the prognosis of patients with solid tumors. D.A. Spandidos 2022-09-20 /pmc/articles/PMC9521627/ /pubmed/36129152 http://dx.doi.org/10.3892/ijo.2022.5424 Text en Copyright: © Ma et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Ma, Xiaoran Wu, Jibiao Wang, Bin Liu, Cun Liu, Lijuan Sun, Changgang Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) |
title | Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) |
title_full | Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) |
title_fullStr | Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) |
title_full_unstemmed | Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) |
title_short | Epigenetic modifications: Critical participants of the PD-L1 regulatory mechanism in solid tumors (Review) |
title_sort | epigenetic modifications: critical participants of the pd-l1 regulatory mechanism in solid tumors (review) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521627/ https://www.ncbi.nlm.nih.gov/pubmed/36129152 http://dx.doi.org/10.3892/ijo.2022.5424 |
work_keys_str_mv | AT maxiaoran epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview AT wujibiao epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview AT wangbin epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview AT liucun epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview AT liulijuan epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview AT sunchanggang epigeneticmodificationscriticalparticipantsofthepdl1regulatorymechanisminsolidtumorsreview |